COMBIGAN® is a fixed-combination therapy of two active substances: brimonidine, an α-2 adrenergic receptor agonist, and timolol, a β-blocker1
The brimonidine and timolol in COMBIGAN® decrease IOP by complementary mechanisms of action1
COMBIGAN® UD (brimonidine 0.2%/timolol 0.5%))
Evidence suggests that COMBIGAN® offers a dual mechanism of action1
COMBIGAN® is thought to lower IOP by enhancing uveoscleral outflow and reducing aqueous humor formation.1
- Reduces aqueous humor formation in the ciliary body1,2
- Enhances uveoscleral outflow1
Image adapted from American Academy of Ophthalmology. 2017.3 Copy from COMBIGAN® Summary of Product Characteristics and Cleveland Clinic. 2022.COM1,2
Administration and dosing for COMBIGAN®
COMBIGAN® combines brimonidine 0.2% and timolol 0.5% in a single bottle for one drop twice a day1
The recommended dose is one drop of COMBIGAN® in the affected eye(s) twice daily, approximately 12 hours apart.1
The recommended dose is one drop of COMBIGAN® in the affected eye(s) twice daily, approximately 12 hours apart.1
COMBIGAN® is indicated for the reduction of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers.1
COMBIGAN® may not be suitable for some of your patients
COMBIGAN® has several contraindications:1
Hypersensitivity to the active substances (brimonidine, timolol) or to any of the excipients (benzalkonium chloride; sodium phosphate; monobasic monohydrate; sodium phosphate; dibasic heptahydrate; hydrochloric acid or sodium hydroxide to adjust pH; and purified water).
Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease.
Sinus bradycardia, sick sinus syndrome sino-atrial block, second or third degree atrioventricular block not controlled with a pace-maker, overt cardiac failure, cardiogenic shock.
Use in neonates and infants (less than 2 years of age).
Patients receiving MAO inhibitor therapy.
Patients on antidepressants which affect noradrenergic transmission (e.g., tricyclic antidepressants and mianserin).
Please refer to COMBIGAN® Summary of Product Characteristics for full safety information and precautions for use.
COMBIGAN® is indicated for the reduction of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers.1
Based on 12-month clinical data, the most commonly reported ADRs were conjunctival hyperemia (approximately 15% of patients) and burning sensation in the eye (approximately 11% of patients). The majority of these cases was mild and led to discontinuation rates of only 3.4% and 0.5% respectively.1
Please refer to COMBIGAN® Summary of Product Characteristics for further information on adverse events.
COMBIGAN® is indicated for the reduction of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers.1
Based on 12-month clinical data, the most commonly reported ADRs were conjunctival hyperemia (approximately 15% of patients) and burning sensation in the eye (approximately 11% of patients). The majority of these cases was mild and led to discontinuation rates of only 3.4% and 0.5% respectively.1
Please refer to COMBIGAN® Summary of Product Characteristics for further information on adverse events.